Abstract:Background:Neoadjuvant chemoimmunotherapy is an important therapeutic modality for resectable nonsmall cell lung cancer (NSCLC). The roles of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in predicting the efficacy and prognosis of patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy remain uncertain. This study aimed to explore the association of baseline and preoperative NLR, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio with the treatment response and survival of patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy.Materials and methods:Data of patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy between May 2019 and July 2022 at our institute, were retrospectively analyzed. Peripheral blood cell counts were obtained at baseline and before surgery. Data that may affect treatment efficacy were also collected and analyzed, including age, sex, BMI, cumulative smoking exposure, pathological type, clinical stage, PD-L1 tumor proportion score, immune checkpoint inhibitors, dosage of neoadjuvant therapy, duration from final therapy to surgery, and baseline and preoperative oncological markers. The present work has been reported in compliance with REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria and guidelines (Supplemental Digital Content 1, http://links.lww.com/JS9/A860).Results:A total of 116 patients were included in the study. Univariate logistic regression analysis showed that a higher baseline NLR (P=0.001) and preoperative NLR (P=0.001) were associated with a lower incidence of pathological complete response (pCR) following neoadjuvant therapy. Multivariate analysis indicated that a lower incidence of pCR was achieved in the high baseline NLR group (P=0.014). Higher baseline NLR (P=0.021), preoperative NLR (P=0.004) and higher preoperative CEA levels (P=0.059) were associated with shorter disease-free survival (DFS). Multivariate Cox proportional hazard regression analyses showed that shorter DFS was achieved in the high preoperative NLR group (P=0.033).Conclusion:In patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy, a higher baseline NLR was associated with a lower incidence of pCR, and a higher preoperative NLR was associated with a shorter DFS. However, a future prospective study with a large sample size and long-term follow-up is needed to verify the predictive value of NLR in these patients.

Pretreatment High Cholesterol and Low Neutrophils Predict Complete Pathological Response after Neoadjuvant Short‑course Radiotherapy Followed by Chemotherapy and Immunotherapy in Locally Advanced Rectal Cancer

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Clinical Study on Locally Advanced Rectal Cancer Patients with Pathological Complete Response ;after Neoadjuvant Chemoradiotherapy

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial.

Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Assessing the predictive value of clinical factors to pathological complete response for locally advanced rectal cancer: An analysis of 124 patients

A Prognostic Analysis of Patients with Pathologic Complete Response after Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer

Value of Pretreatment Inflammation-nutrition Score to Predict Non-response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study

Prediction of pathologic complete response to neoadjuvant chemoradiation in locally advanced rectal cancer

Clinical Factors of Post-Chemoradiotherapy As Valuable Indicators for Pathological Complete Response in Locally Advanced Rectal Cancer

Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy

High Preoperative Peripheral Blood Neutrophil Predicts Poor Outcome in Rectal Cancer Treated with Neoadjunctive Chemoradiation Therapy.

[Predictive Factors of Pathological Complete Response after Neoadjuvant Chemoradiotherapy for Middle-Low Rectal Cancer].

Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation

Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints

Pretreatment Neutrophil to Lymphocyte Ratio As a Predictor of Pathological Complete Response to Neoadjuvant Immunotherapy in Early Breast Cancer.

Pre-Treatment Computed Tomography Radiomics for Predicting the Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Retrospective Study

Factors associated with pathological complete remission after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a real-world clinical setting

[Clinical Factors of Pathological Complete Response after Neoadjuvant Chemoradiotherapy in Rectal Cancer].